> Detailanzeige

Jensen, AD; Münter, MW; Bischoff, H; Haselmann, R; Timke, C; Krempien, R; Sterzing, F; Nill, S; Heeger, S; Hoess, A; Haberkorn, U; Huber, PE; Steins, M; Thomas, M; Debus, J; Herfarth, KK

Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518)

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518)
  • Beteiligte: Jensen, AD; Münter, MW; Bischoff, H; Haselmann, R; Timke, C; Krempien, R; Sterzing, F; Nill, S; Heeger, S; Hoess, A; Haberkorn, U; Huber, PE; Steins, M; Thomas, M; Debus, J; Herfarth, KK
  • Erschienen: Springer Science and Business Media LLC, 2006
  • Erschienen in: BMC Cancer, 6 (2006) 1
  • Sprache: Englisch
  • DOI: 10.1186/1471-2407-6-122
  • ISSN: 1471-2407
  • Schlagwörter: Cancer Research ; Genetics ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Even today, treatment of Stage III NSCLC still poses a serious challenge. So far, surgical resection is the treatment of choice. Patients whose tumour is not resectable or who are unfit to undergo surgery are usually referred to a combined radio-chemotherapy. However, combined radio-chemotherapeutic treatment is also associated with sometimes marked side effects but has been shown to be more efficient than radiation therapy alone.</jats:p> <jats:p>Nevertheless, there is a significant subset of patients whose overall condition does not permit administration of chemotherapy in a combined-modality treatment.</jats:p> <jats:p>It could be demonstrated though, that NSCLCs often exhibit over-expression of EGF-receptors hence providing an excellent target for the monoclonal EGFR-antagonist cetuximab (Erbitux<jats:sup>®</jats:sup>) which has already been shown to be effective in colorectal as well as head-and-neck tumours with comparatively mild side-effects.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods/design</jats:title> <jats:p>The NEAR trial is a prospective phase II feasibility study combining a monoclonal EGF-receptor antibody with loco-regional irradiation in patients with stage III NSCLC. This trial aims at testing the combination's efficacy and rate of development of distant metastases with an accrual of 30 patients.</jats:p> <jats:p>Patients receive weekly infusions of cetuximab (Erbitux<jats:sup>®</jats:sup>) plus loco-regional radiation therapy as intensity-modulated radiation therapy. After conclusion of radiation treatment patients continue to receive weekly cetuximab for 13 more cycles.</jats:p> </jats:sec> <jats:sec> <jats:title>Discussion</jats:title> <jats:p>The primary objective of the NEAR trial is to evaluate toxicities and feasibility of the combined treatment with cetuximab (Erbitux<jats:sup>®</jats:sup>) and IMRT loco-regional irradiation.</jats:p> <jats:p>Secondary objectives are remission rates, 3-year-survival and local/systemic progression-free survival.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang